ethyl phenylacetyl-Pro-Gly

03/01/2009 - "Noopept reduces the postischemic functional and metabolic disorders in the brain of rats with different sensitivity to hypoxia."
03/01/2009 - "Noopept (peptide preparation), injected (0.5 mg/kg) during 7 days after occlusion of the carotid arteries, reduced the neurological disorders in rats with high and low sensitivity to hypoxia and improved their survival during the postischemic period. "
03/01/2009 - "Noopept normalized behavior disordered by cerebral ischemia (according to the open field and elevated plus maze tests), prevented accumulation of LPO products and inhibition of antioxidant systems in the brain of rats with high and low sensitivity to hypoxia. "
01/01/1998 - "The authors recommend novel nootrops (nooglutyl, mexidol, semax and GVS-111) for the pharmacological correction of mnestic disorders consequent to hypoxia or cerebral ischemia."
01/01/2013 - "It has been established in experiments in rats that some nootropic substances (oxyracetam, aniracetam, nooglutil, mexidol, new 3-hydroxypyridine derivative SK-170, piracetam and noopept) produce marked antiamnestic effect on various models of amnesia (induced by microwave irradiation, acute hypoxia, and motion sickness). "

03/01/2009 - "Noopept (peptide preparation), injected (0.5 mg/kg) during 7 days after occlusion of the carotid arteries, reduced the neurological disorders in rats with high and low sensitivity to hypoxia and improved their survival during the postischemic period. "

07/01/2008 - "Noopept efficiency in many models of Alzheimer disease, its high bioavailability and low toxicity suggest this dipeptide for further studies as a potential agent for the treatment of this condition (initial and moderate phases)."
01/01/2014 - "Our previous experiments have demonstrated the cognition restoring effect of noopept in several animal models of Alzheimer disease (AD). "
09/01/2008 - "Moreover, therapeutic effectiveness of Noopept should be evaluated at the initial stage of Alzheimer's disease."
09/01/2008 - "In light of this our findings suggest that Noopept holds much promise to prevent the development of Alzheimer's disease in patients with mild cognitive impairment. "
07/01/2008 - "Noopept efficiency in experimental Alzheimer disease (cognitive deficiency caused by beta-amyloid25-35 injection into Meynert basal nuclei of rats)."

03/01/2009 - "Hence, noopept exhibited a neuroprotective effect in cerebral ischemia."
09/01/2002 - "The pronounced neuroprotective effect of noopept was demonstrated both in vivo (in cases of various forms of brain ischemia) and in vitro (on various neuronal models). "
03/01/2009 - "Noopept normalized behavior disordered by cerebral ischemia (according to the open field and elevated plus maze tests), prevented accumulation of LPO products and inhibition of antioxidant systems in the brain of rats with high and low sensitivity to hypoxia. "
07/01/2006 - "[Neuroprotective activity of the proline-containing dipeptide noopept on the model of brain ischemia induced by the middle cerebral artery occlusion]."
01/01/1998 - "The authors recommend novel nootrops (nooglutyl, mexidol, semax and GVS-111) for the pharmacological correction of mnestic disorders consequent to hypoxia or cerebral ischemia."

01/01/2011 - "The results have demonstrated that noopept, used in dose 20 mg daily during 2 months, improves cognitive functions in stroke patients and has a high level of safety."
01/01/2011 - "The present open prospective study included 60 patients with stroke treated with noopept during 12 months. "
01/01/2011 - "[Noopept in the treatment of mild cognitive impairment in patients with stroke]."
07/01/2006 - "The data on noopept efficacy on the model of the extensive ischemic injury of brain cortex show that this drug has good prospects for use in the neuroprotective treatment of stroke."
09/01/1999 - "Memory restoring and neuroprotective effects of the proline-containing dipeptide, GVS-111, in a photochemical stroke model."